Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Empagliflozin has expanded beyond glucose management to become a standard-of-care agent for cardiovascular and renal protection in high-risk patients.

FDA-Approved Uses

• Type 2 diabetes mellitus — adjunct to diet and exercise to improve glycemic control in adults
• Cardiovascular risk reduction — reduce risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease (EMPA-REG OUTCOME trial landmark approval)
• Heart failure with reduced ejection fraction (HFrEF) — reduce risk of cardiovascular death and hospitalization for heart failure in adults, with or without type 2 diabetes
• Heart failure with preserved ejection fraction (HFpEF) — reduce risk of cardiovascular death and worsening heart failure in adults
• Chronic kidney disease (CKD) — reduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD at risk for disease progression

How It Works

SGLT2 (sodium-glucose cotransporter-2) is a protein in the proximal tubule of the kidney responsible for reabsorbing about 90% of filtered glucose back into the bloodstream. Empagliflozin reversibly inhibits SGLT2, preventing this reabsorption. The result is glucosuria — glucose is excreted in the urine — which lowers blood glucose levels in an insulin-independent manner.

The glycosuria also causes osmotic diuresis (water follows the sugar into the urine), leading to modest blood pressure reduction and mild volume depletion. This hemodynamic effect may partly explain the cardiovascular benefits. Additional proposed mechanisms for organ protection include reductions in intraglomerular pressure (protecting the kidneys), reduced cardiac preload and afterload, shifts in cardiac energy substrate utilization toward ketone bodies, and anti-inflammatory effects.

Because the mechanism is insulin-independent, empagliflozin works regardless of insulin secretory capacity and carries a low intrinsic risk of hypoglycemia (except when combined with insulin or sulfonylureas).

Side Effects

Common

• Genital mycotic infections (yeast infections) — in women and, less commonly, men; due to increased glucose in urine
• Urinary tract infections (UTIs)
• Increased urination (polyuria) and thirst
• Volume depletion symptoms — dizziness, lightheadedness, especially in elderly or those on diuretics
• Mild weight loss
• Nasopharyngitis and upper respiratory infections
• Dyslipidemia — modest increases in LDL cholesterol

Serious

• Diabetic ketoacidosis (DKA) — can occur with glucose levels that appear only mildly elevated ("euglycemic DKA"); presentation with nausea, vomiting, abdominal pain, fatigue, and difficulty breathing
• Fournier's gangrene — rare but life-threatening necrotizing fasciitis of the perineum; requires emergency surgical debridement
• Acute kidney injury — particularly with volume depletion; hold during illness, surgery, or severe dehydration
• Lower limb amputations — class concern with some SGLT2 inhibitors (primarily canagliflozin; less clear with empagliflozin); monitor foot care
• Urosepsis and pyelonephritis — serious urinary tract infections requiring hospitalization

Drug Interactions

Drug / Class	Interaction	Clinical Significance
Insulin and insulin secretagogues (sulfonylureas, meglitinides)	Additive glucose-lowering effect; increased risk of hypoglycemia when combined	High — dose reduction of insulin or sulfonylurea may be needed when adding empagliflozin
Diuretics (loop, thiazide)	Additive diuretic effect; increased risk of volume depletion, dehydration, and acute kidney injury	Moderate–High — monitor renal function and electrolytes; use caution in elderly patients
ACE inhibitors / ARBs	Combined effect on blood pressure and renal hemodynamics; additive hypotensive and renal effects	Moderate — combination is common and often beneficial (both are kidney protective), but monitor renal function and blood pressure
UGT enzyme inducers (rifampin)	Rifampin increases empagliflozin glucuronidation, reducing plasma levels	Moderate — glycemic effect may be attenuated; consider alternative antibiotic if possible
Antihypertensives (multiple classes)	Enhanced blood pressure lowering due to empagliflozin's diuretic and hemodynamic effects	Moderate — monitor blood pressure, especially on initiation
Digoxin	Empagliflozin may modestly increase digoxin exposure through volume changes	Low–Moderate — monitor digoxin levels if empagliflozin is initiated or stopped
NSAIDs	Additive risk of acute kidney injury, especially in volume-depleted patients	Moderate — avoid NSAIDs in patients on empagliflozin who are dehydrated or have reduced kidney function

Warnings & Contraindications

Key Precautions

• Hold before surgery: Empagliflozin should generally be held for 3–4 days before elective surgery due to DKA risk; ensure glucose monitoring during this period
• Sick day management: Instruct patients to hold empagliflozin during significant illness, fasting, or dehydration
• Genital hygiene: Counsel patients on maintaining good genital hygiene to reduce risk of yeast infections
• Pregnancy: Should be discontinued at or before the 2nd trimester; fetal kidney toxicity risk
• Volume status: Assess renal function and volume status before initiating; use caution in elderly or patients on multiple blood pressure medications

Frequently Asked Questions

How does empagliflozin protect the heart and kidneys?

The cardiovascular and renal benefits of empagliflozin are robust and go well beyond glucose lowering. The EMPA-REG OUTCOME trial showed a 38% reduction in cardiovascular death among high-risk patients. Proposed mechanisms include: reduction in cardiac preload (via diuresis), reduction in afterload, reduced intraglomerular pressure protecting the kidneys, favorable cardiac energy substrate shifts (toward ketone use), and anti-inflammatory effects. These benefits occur in patients with and without diabetes, which is why heart failure and CKD are now standalone indications.

What is euglycemic DKA and why does it happen with SGLT2 inhibitors?

Diabetic ketoacidosis normally presents with very high blood glucose. With SGLT2 inhibitors, DKA can occur with near-normal glucose levels because the drug is excreting the excess sugar in the urine. This masks the high glucose that would normally prompt evaluation. The ketosis and acidosis are driven by insulin deficiency or other triggers (fasting, surgery, illness, alcohol), and the glucose-lowering effect of the drug obscures the picture. Patients and clinicians need to think of DKA even when glucose is not markedly elevated.

Can empagliflozin cause weight loss?

Yes, modest weight loss is commonly observed with empagliflozin, typically in the range of 2–3 kg on average. The weight loss comes from two sources: glycosuria (calories lost as glucose in the urine) and mild diuresis (loss of fluid). The weight lost is predominantly fat mass with some fluid. This effect is a clinical advantage in patients with type 2 diabetes, where weight management is important.

Is empagliflozin appropriate for patients without diabetes?

Yes — increasingly so. The FDA approvals for heart failure (both HFrEF and HFpEF) and chronic kidney disease apply regardless of whether the patient has type 2 diabetes. The landmark EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY trials all included substantial proportions of patients without diabetes, with similar benefits. Cardiologists and nephrologists now prescribe empagliflozin independently of diabetes management as organ-protective therapy.

→ Type 2 Diabetes Medications Guide